ChromaDex wins US government contract for scientific services
The new contract with the General Services Administration (GSA), which took effect on March 1, covers all aspects of food and dietary supplement testing, analytical method development and validation, contract research services, report and manuscript preparation and laboratory technique training.
Food and Drug Administration
CEO and co-founder Frank Jaksch told NutraIngredients-USA.com: “Any government agency that has need of… (our) analytical services can use this contract to purchase services… ChromaDex works with agencies such as: FDA (Food and Drug Administration), NIH (National Institutes of Health), NIST (National Institute of Standards and Technology), USDA (United States Department of Agriculture) and EPA (Environmental Protection Agency).”
The GSA contract is open-ended in that any company whose products or services match the requirements of the specification can submit a proposal. “There are 62 categories of commercial products and services that vendors may apply for a GSA contract under,” said the spokesman. “Known as schedules, these categories cover everything from industrial products, vehicles, computers and office products, to most categories of professional services.”
The five-year contract is reviewed annually and can be renewed for three additional five-year periods. To keep the contract in place, the company must achieve certain levels of sales to government agencies each year.
11m commercial supplies
Government contracts with commercial firms provide federal agencies with access to over 11m commercial supplies (products) and services that can be ordered directly from GSA Schedule contractors, according to ChromaDex.
Jaksch said: “This long term supply contract enables government agencies to quickly and easily utilize ChromaDex services without going through lengthy competitive bid processes. We currently serve a number of government agencies, and this contract will make it quicker and easier for them to do business with ChromaDex.”
The company was unable to confirm how many tests would be conducted each year under the terms of this arrangement or what proportion of its total business was accounted for by federal agencies.
